Key Stats for Merck Stock
- 52-Week Range: $73 to $125
- Current Price: $119
- Street Mean Target: $130
- Street High Target: $150
- TIKR Model Target (Dec. 2030): $188
- Analyst Consensus: 15 Buys / 4 Outperforms / 10 Holds / 0 Sells
What Happened?
Merck & Co. (MRK), the pharmaceutical giant behind Keytruda (the world’s best-selling cancer drug), is in the middle of a deliberate transformation that is producing one of the most misread earnings setups in large-cap pharma.
The $6.7 billion acquisition of Terns Pharmaceuticals, announced March 25, will deliver a $5.8 billion one-time R&D charge to 2026 results, dragging reported EPS to around $5 per share from $8.98 in 2025.
Strip out that charge, and the underlying midpoint lands at around $9.03 per share, meaning the operational earnings trajectory is flat-to-growing while the headline number collapses.
The Terns deal brings TERN-701, an investigational oral drug for chronic myeloid leukemia (a bone marrow cancer characterized by uncontrolled leukemia cell growth) that showed a 75% major molecular response rate in previously treated patients, a result that an analyst at Scotiabank described as having “peak sales potential of tens of billions of dollars.”
On the Q4 2025 earnings call, CEO Robert Davis stated that Merck now has “line of sight to over $70 billion of potential commercial opportunity by the mid-2030s, $20 billion more than just a year ago and more than double consensus 2028 peak Keytruda revenue of $35 billion,” tying the Terns deal directly to the company’s post-patent survival plan.
Keytruda, the immunotherapy that generated over $30 billion in 2025 and accounted for nearly half of Merck revenue, faces U.S. patent expiry in 2028, a cliff the company is spending aggressively to avoid.
The pipeline Merck is building to replace that revenue includes enlicitide, an oral PCSK9 inhibitor (a cholesterol-lowering pill designed to work like an injectable biologic) that cut LDL cholesterol ~65% in a Phase 3 head-to-head trial and has received an FDA Commissioner’s National Priority Voucher targeting a launch as early as 2026.
Wall Street’s Take on MRK Stock
The acquisition charges distorting 2026 earnings are compressing the market’s view of Merck stock at exactly the moment free cash flow is set to accelerate.
Merck’s FCF is expected to surge from $12.36 billion in 2025 to around $16 billion in 2026 and around $24 billion in 2027, a 52% single-year leap, as one-time acquisition charges clear and new product launches compound, making the headline EPS decline a temporary accounting event, not an operational one.
Wall Street has not abandoned the thesis: 19 of 29 covering analysts carry buy or outperform ratings, with a mean price target of $129.81 implying around 9% upside, and the consensus has been migrating higher since MRK stock bottomed near $73 last year.
The target spread runs from $100 to $150, and the distance between those poles reflects a genuine debate: the low end prices in a severe Keytruda LOE without successful replacement revenue, while the $150 bull case assumes enlicitide and TERN-701 are both approved and ramping before the patent cliff arrives.
Priced at around 12x the street’s 2027 normalized EPS estimate of roughly $10, Merck stock trades at a meaningful discount to the 15x to 17x range it has historically commanded, leaving Merck stock appearing undervalued against a pipeline that now spans oncology, cardiovascular, respiratory, and rare disease with $70 billion in identified non-risk-adjusted commercial opportunity by the mid-2030s.
CFO Caroline Litchfield confirmed the adjusted 2026 EPS midpoint lands at around $9, excluding the around $3.65 Cidara charge and around $0.30 in ongoing financing costs.
If enlicitide stumbles in the regulatory process or TERN-701 phase 3 data disappoints, the gap left by Keytruda’s LOE becomes structurally harder to fill.
The April 30 Q1 2026 earnings call is the first chance for management to update guidance post the Terns tender close: watch for the adjusted EPS ex-Cidara figure management will use to confirm the around $9 midpoint is tracking.
What Does the Valuation Model Say?
TIKR’s mid-case model targets around $188 per share for MRK, implying a total return of ~58% over roughly 5 years, anchored to a net income margin assumption of around 34%, a figure consistent with Merck’s 2025 actual of around 35% and supported by the FCF inflection as acquisition-related costs roll off.
At roughly $119, an IRR of around 6% annually through 2030 against a business with $70 billion in identified pipeline potential and free cash flow set to nearly double by 2027 makes Merck stock undervalued at current multiples, with the margin of safety widening as one-time charges clear and operational earnings resurface.
The central tension for Merck stock investors is a timing problem: the pipeline is real, the patent cliff is real, and the market’s verdict depends entirely on which one arrives faster.
Bull Case
- Enlicitide filing imminent with FDA Commissioner’s Priority Voucher in hand, targeting 80 million under-treated lipid patients across the U.S., Europe, and Japan; CFO Litchfield cited an “ordinary time line” pointing to a Q1 2027 launch
- TERN-701 Phase 3 program initiating in both frontline and second-line CML settings, targeting around 18,000 new annual diagnoses across the U.S., Japan, and key European markets with multibillion-dollar peak sales potential
- WINREVAIR (sotatercept) generating $467 million in Q4 2025 alone and advancing into CpcPH-HFpEF after Phase 2 CADENCE met its primary endpoint, opening a new patient population beyond the existing PAH label
- FCF expected to reach around $24 billion in 2027, up from $12.36 billion in 2025, providing capital for continued M&A within Merck’s stated sub-$15 billion deal sweet spot
- KEYTRUDA QLEX subcutaneous formulation targeting 30% to 40% adoption ahead of the IV biosimilar entry, extending the Keytruda revenue tail through the LOE window
Bear Case
- 2026 consensus revenue of around $67 billion implies only 2.5% growth while the business absorbs $2.5 billion in headwinds from JANUVIA and BRIDION genericization plus declining LAGEVRIO demand
- Enlicitide faces a fasting requirement that a competing oral PCSK9 program at AstraZeneca is attempting to undercut, and the ACC/AHA LDL guideline changes needed to expand the addressable market remain unconfirmed
- The $6.7 billion Terns acquisition paid only a 6% premium to last close, below the 38% to 140% range seen in comparable pharma buyouts, signaling limited competitive conviction from other bidders for TERN-701
- GARDASIL revenue projected stable in 2026 after a 35% Q4 2025 decline driven by China and Japan demand weakness, removing a second growth driver alongside Keytruda ahead of the LOE
- Keytruda IP protection past December 2028 hinges on two additional patents (method of use, method of making) that management has growing confidence in defending but has not yet confirmed through litigation
Should You Invest in Merck & Co., Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up MRK stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Merck & Co., Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze MRK stock on TIKR for Free →
